Advanced

Risk of Dying From Prostate Cancer in Men Randomized to Screening Differences Between Attendees and Nonattendees

Bergdahl, Anna Grenabo; Aus, Gunnar; Lilja, Hans LU and Hugosson, Jonas (2009) In Cancer 115(24). p.5672-5679
Abstract
BACKGROUND: Although the true benefits and disadvantages of prostate cancer screening are still not known, the analysis of fatal cases is important for increasing knowledge of the effects of prostate cancer screening on mortality. Who dies from prostate cancer despite participation in a population-based prostate-specific antigen (PSA) screening program? METHODS: From the Goteborg branch of the European Randomized study of Screening for Prostate Cancer, 10,000 men randomly assigned to active PSA-screening every second year formed the basis of the present study. Prostate cancer mortality was attributed to whether the men were attendees in the screening program (attending at least once) or nonattendees. RESULTS: Thirty-nine men died from... (More)
BACKGROUND: Although the true benefits and disadvantages of prostate cancer screening are still not known, the analysis of fatal cases is important for increasing knowledge of the effects of prostate cancer screening on mortality. Who dies from prostate cancer despite participation in a population-based prostate-specific antigen (PSA) screening program? METHODS: From the Goteborg branch of the European Randomized study of Screening for Prostate Cancer, 10,000 men randomly assigned to active PSA-screening every second year formed the basis of the present study. Prostate cancer mortality was attributed to whether the men were attendees in the screening program (attending at least once) or nonattendees. RESULTS: Thirty-nine men died from prostate cancer during the first 13 years. Both overall (34% vs 13 %; P <.0001) and cancer-specific mortality (0.8% vs 0.3 %; P < .005) were found to be significantly higher among nonattendees compared with attendees. Furthermore, the majority of deaths (12 of 18) among screening attendees were in men diagnosed at first screening (prevalent cases). Only 6 deaths (including 3 interval cases) were noted among men complying with the biennial screening program. CONCLUSIONS: Nonattendees in prostate cancer screening constitute a high-risk group for both death from prostate cancer and death from other causes comparable to that described in other cancer screening programs. Cancer 2009;115:5672-9. (C) 2009 American Cancer Society. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
patient compliance, mortality, screening, prostate cancer, diagnosis
in
Cancer
volume
115
issue
24
pages
5672 - 5679
publisher
John Wiley & Sons
external identifiers
  • wos:000272545400011
  • scopus:73149115536
ISSN
1097-0142
DOI
10.1002/cncr.24680
language
English
LU publication?
yes
id
28584041-3085-46e8-a8ea-e305d86e361a (old id 1532621)
date added to LUP
2010-01-29 11:01:35
date last changed
2017-01-01 04:25:56
@article{28584041-3085-46e8-a8ea-e305d86e361a,
  abstract     = {BACKGROUND: Although the true benefits and disadvantages of prostate cancer screening are still not known, the analysis of fatal cases is important for increasing knowledge of the effects of prostate cancer screening on mortality. Who dies from prostate cancer despite participation in a population-based prostate-specific antigen (PSA) screening program? METHODS: From the Goteborg branch of the European Randomized study of Screening for Prostate Cancer, 10,000 men randomly assigned to active PSA-screening every second year formed the basis of the present study. Prostate cancer mortality was attributed to whether the men were attendees in the screening program (attending at least once) or nonattendees. RESULTS: Thirty-nine men died from prostate cancer during the first 13 years. Both overall (34% vs 13 %; P &lt;.0001) and cancer-specific mortality (0.8% vs 0.3 %; P &lt; .005) were found to be significantly higher among nonattendees compared with attendees. Furthermore, the majority of deaths (12 of 18) among screening attendees were in men diagnosed at first screening (prevalent cases). Only 6 deaths (including 3 interval cases) were noted among men complying with the biennial screening program. CONCLUSIONS: Nonattendees in prostate cancer screening constitute a high-risk group for both death from prostate cancer and death from other causes comparable to that described in other cancer screening programs. Cancer 2009;115:5672-9. (C) 2009 American Cancer Society.},
  author       = {Bergdahl, Anna Grenabo and Aus, Gunnar and Lilja, Hans and Hugosson, Jonas},
  issn         = {1097-0142},
  keyword      = {patient compliance,mortality,screening,prostate cancer,diagnosis},
  language     = {eng},
  number       = {24},
  pages        = {5672--5679},
  publisher    = {John Wiley & Sons},
  series       = {Cancer},
  title        = {Risk of Dying From Prostate Cancer in Men Randomized to Screening Differences Between Attendees and Nonattendees},
  url          = {http://dx.doi.org/10.1002/cncr.24680},
  volume       = {115},
  year         = {2009},
}